Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: that the unit size of the company's repeatable business is escalating, with comparisons to its own past, already real and recurring, and early in the trend. Looking at the transcript, management discusses various business lines. For example, NovaSeq placements, consumables, microarray, etc. But does management say that each new deal or order is larger than before? They talk about strong demand, growth in consumables, but not about the size of individual orders increasing. They mention that NovaSeq shipments are as expected, and that the upgrade cycle is multi-year. They don't say that new customers are starting at larger scale or that deals are bigger. They mention partnerships with Loxo and BMS, but those are new collaborations, not necessarily larger than previous ones. They don't compare sizes. They talk about the Harvard Pilgrim study, but that's a study, not a business engagement. They mention that the microarray business had a strong quarter, but that's revenue growth, not necessarily larger individual orders. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. There is no such statement. Management talks about growth in volume, but not about the size of each engagement increasing. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.